NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Tuesday that its revenues in the first quarter were down 29 percent year over year but the firm still beat the consensus analyst estimate on the top and bottom lines.

The company said that for the three months ended March 31, revenues totaled $7.9 million, compared to $11.1 million in the year-ago quarter, and easily surpassing the average analyst estimate of $6.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.